
Alixia
Alixia is a YC Winter 2022 (W22) company. Based in San Francisco, CA, USA. Team of 2.
About Alixia
Summary
Alixia develops small-molecule compounds that target the tumor microenvironment to overcome cancer drug resistance. Rather than attacking a single mutation, the approach disrupts the metabolic and inflammatory signals shared across multiple cell types, including cancer cells, cancer-associated fibroblasts, immune cells, and senescing normal cells, to collapse the broader tumor ecosystem. The work replaces single-target precision oncology strategies that benefit only a narrow slice of patients with relapsed and refractory solid tumors.
From the Y Combinator listing
Targeting the Tumor Ecosystem to address cancer drug resistance.
Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (2)
- Helen Chen
- Olof Mollstedt
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works